Integrated Diagnostics Secures Additional $10M to Prep for 2013 Launch of Lung Cancer Dx | GenomeWeb

This story originally ran on Feb. 23.

By Adam Bonislawski

Integrated Diagnostics said this week it has secured the third $10 million tranche of its Series A funding upon achieving key milestones in its diagnostic programs.

Specifically, the company has completed clinical trials demonstrating the commercial potential of its proteomic lung cancer diagnostic, InDi CEO and director Albert Luderer told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.